68Ga‐DOTATOC‐PET/MRI and 11C‐5‐HTP‐PET/MRI are superior to 68Ga‐DOTATOC‐PET/CT for neuroendocrine tumour imaging
Authors:
Open Access
- 14 May 2021
- journal article
- research article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 33 (6) , e12981
Abstract
The present study aimed to assess gadoxetate disodium contrast‐enhanced (CE) positron emission tomography (PET)/magnetic resonance imaging (MRI) with 68Ga‐DOTATOC and 11C‐5‐Hydroxy‐tryptophan (11C‐5‐HTP) in comparison with iodine CE 68Ga‐DOTATOC‐PET/computed tomography (CT) for neuroendocrine tumour imaging. Detection rate and reader's confidence were evaluated for each separate image volume: CE‐CT, CE‐MRI including diffusion‐weighted imaging, 68Ga‐DOTATOC‐PET performed at PET/CT, 68Ga‐DOTATOC‐PET performed at PET/MRI and 11C‐5‐HTP‐PET, and for the three combined hybrid examinations 68Ga‐DOTATOC‐PET/MRI, 11C‐5‐HTP‐PET/MRI and 68Ga‐DOTATOC‐PET/CT. In 11 patients, 255 lesions were depicted. 68Ga‐DOTATOC‐PET performed at PET/MRI depicted 72.5%, 68Ga‐DOTATOC‐PET performed at PET/CT depicted 62.7%, 11C‐5‐HTP‐PET depicted 68.2% and CE‐CT depicted 53% of lesions. 68Ga‐DOTATOC‐PET performed at PET/MRI (P < 0.001) and PET/CT (P = 0.02), 11C‐5‐HTP‐PET (P < 0.001) and MRI (P < 0.001) were superior to CT. 68Ga‐DOTATOC‐PET/MRI and 11C‐5‐HTP‐PET/MRI detected 92.5% and 92% of lesions, respectively, and both outperformed 68Ga‐DOTATOC‐PET/CT (65%) (P < 0.001). For liver metastasis imaging, MRI alone was unsurpassed (P < 0.01) and 68Ga‐DOTATOC‐PET/MRI and 11C‐5‐HTP‐PET/MRI outperformed 68Ga‐DOTATOC‐PET/CT (P < 0.001). For lymph node metastasis diagnosis, 68Ga‐DOTATOC‐PET performed at PET/MRI and PET/CT and 11C‐5‐HTP‐PET detected 94%, 94% and 94% of lesions, respectively, and outperformed MRI and CE‐CT alone (P < 0.001). For bone metastasis imaging, 68Ga‐DOTATOC‐PET performed at PET/MRI and PET/CT and 11C‐5‐HTP‐PET performed equally well (P = 0.05) and better than MRI. Reader's confidence was better for 68Ga‐DOTATOC‐PET/MRI and 11C‐5‐HTP‐PET/MRI than for 68Ga‐DOTATOC‐PET/CT. The tumour maximum standardised uptake value and tumour‐to‐liver ratio were both approximately twice as high as for 68Ga‐DOTATOC than for 11C‐5‐HTP. 68Ga‐DOTATOC‐PET/MRI and 11C‐5‐HTP‐PET/MRI provided the highest detection rates and reader's confidence and were both superior to 68Ga‐DOTATOC‐PET/CT, mainly because of the MRI component. The imaging contrast with 68Ga‐DOTATOC was superior to that of 11C‐5‐HTP.Keywords
This publication has 48 references indexed in Scilit:
- Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomenEuropean Radiology, 2013
- Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRICancer Imaging, 2013
- PET-Guided Surgery — High Correlation between Positron Emission Tomography with 11C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine TumoursCancers, 2012
- 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase ProtocolJournal of Nuclear Medicine, 2011
- NANETS Treatment GuidelinesPancreas, 2010
- ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine TumorsNeuroendocrinology, 2010
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone ScintigraphyJournal of Nuclear Medicine, 2009
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survivalAnnals of Oncology, 2008
- Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission TomographyJournal of Clinical Oncology, 2008
- Enzymatic Synthesis of Carboxy-11C-Labelled L-Tyrosine, L-DOPA, L-Tryptophan and 5-Hydroxy-L-tryptophan.Acta Chemica Scandinavica, 1990